Analytical Testing

Understanding Bacterial Endotoxin Testing

Understand the signal behind an endotoxin result, the sample effects that can change it, and what a less-than value really means.

PhD Peptides editorial teamPublished 9 October 20265 min read

A laboratory reference. No dosing or administration guidance.

A report says that endotoxin was below its reporting limit. What has the laboratory established, and how does that result sit beside purity or sterility data? Bacterial endotoxin testing measures a specific target: activity associated with lipopolysaccharide from Gram-negative bacteria. Understanding the assay, sample and units turns a small line on the certificate into useful analytical information.

The result is most informative when read with the question the test was designed to answer. A method examining endotoxin and a method looking for recoverable microorganisms can both be valid without giving the same kind of evidence.

Editorial illustration: a clear microplate beside a plate reader and a laboratory micropipette.
Editorial illustration: A microplate and reader at an assay bench. No endotoxin measurements are represented.

The target is a bacterial component, not a living cell

Lipopolysaccharide, usually shortened to LPS, forms part of the outer membrane of many Gram-negative bacteria. Its structure includes lipid A and carbohydrate regions. Experimental work comparing bacterial and synthetic lipid A helped establish its central role in endotoxin activity. Rietschel and colleagues on lipid A.

The target need not be a living organism. That explains why an endotoxin observation and a culture result can differ without contradicting one another. The broader category of pyrogens also contains substances beyond Gram-negative endotoxin, so this targeted assay is neither a sterility test nor a complete pyrogen assessment. FDA’s explanation of endotoxins and pyrogens.

How a small amount becomes a measurable signal

Traditional Limulus amoebocyte lysate, or LAL, reagents use components derived from horseshoe-crab blood cells. Endotoxin activates factor C and a reaction cascade. The assay then observes an outcome such as clot formation, turbidity or colour. Some LAL systems also have a β-glucan-sensitive route, making reagent specificity important. FDA’s technical presentation on assay principles.

What the assay observes
TechniqueReadoutUseful distinction
Gel-clotClot formationOften a limit test rather than a precise concentration
TurbidimetricChange in turbidityInterpreted against calibration and the validated range
ChromogenicColour generated by the reactionSample colour or interference needs evaluation
Recombinant reagentSignal from a defined recombinant systemReadout depends on the assay used

Recombinant factor C, or rFC, uses a manufactured version of the endotoxin-sensitive protein. A multi-year proficiency study found comparable performance for the LAL and rFC assays it examined. That is useful evidence about the tested comparison, rather than a promise that every reagent behaves identically. LAL and rFC proficiency testing.

The regulatory discussion has developed with the technology. FDA’s 2026 clarification accommodates recombinant approaches and refers to USP Chapter 86, while emphasising suitability for the intended material. Reading the method name and version is therefore more helpful than assuming every endotoxin report used the same assay. FDA’s current clarification.

The sample is part of the measurement

An assay must be able to detect its target with the sample present. Formulation components can inhibit or enhance the signal. In a study comparing rFC and LAL with biopharmaceutical samples, interference depended on the material and assay, and the investigators evaluated suitable sample conditions. The rFC application study.

Time can matter as well. A study of low endotoxin recovery found that naturally occurring endotoxin became less detectable in particular surfactant and chelating matrices, with behaviour depending on source and conditions. A weaker signal did not, by itself, demonstrate that the target had disappeared. Research on endotoxin masking.

FDA’s current Q&A links sample handling and storage to laboratory evidence of assayable endotoxin stability. This gives the sample’s history a place in the interpretation alongside reagent and instrument performance. FDA: sample storage and handling.

Three questions that should stay separate

01Bacterial endotoxins

Lipopolysaccharides or lipooligosaccharides from Gram-negative bacteria.

02Other pyrogens

Non-endotoxin substances that can produce a pyrogenic response.

03Viable microorganisms

Living organisms assessed by microbiological methods.

An endotoxin result is not a sterility result or a test for every possible pyrogen.

Peptide chromatography, endotoxin testing and sterility testing examine different targets. Their results complement each other when the method and sample remain clear.

Reading the units without losing the meaning

Reports commonly express results in endotoxin units, or EU, with a denominator such as mL or mg. These are standardised activity units. NIBSC’s documentation assigns a defined unitage to its endotoxin reference preparation. NIBSC reference-standard documentation.

EU should not be treated as a universal mass conversion for every LPS preparation. An experimental comparison of divergent LPS structures found that assay responses could differ. The divergent-LPS comparison. The denominator also matters: results per mL and per mg cannot be ranked by comparing their printed numbers alone.

Two less-than results

Suppose two hypothetical reports state <0.05 EU/mL and <0.5 EU/mL. Each result falls below its own reporting limit. The second does not establish the lower bound achieved by the first, and neither is a measured zero.

For a meaningful comparison, the reader needs the same sample basis and adequate suitability controls. Whether either limit answers the research question depends on the experiment’s predefined criterion. These numbers illustrate interpretation; they are not a product specification or human-use threshold.

Why the distinction matters in an experiment

An observed signal need not come entirely from the named reagent. Primary research found that residual endotoxin in recombinant-protein preparations could activate a sensitive cell-based reporter system. The study illustrates how contamination can confound attribution within an experiment. Residual endotoxin contamination in recombinant proteins.

A useful report therefore preserves the batch, sample description, method, suitability outcome, units and reporting limit. Together, those details explain what was measured and how far the conclusion reaches. They also help distinguish an unexpected experimental result from an unresolved question about the material.

Sources and further reading

  1. Rietschel et al. Chemical structure and biologic activity of bacterial and synthetic lipid A (1987)
  2. FDA: Bacterial Endotoxins/Pyrogens (1985)
  3. FDA perspective on recombinant reagents, USP-hosted technical presentation
  4. Comparison of LAL and rFC Assays: Proficiency Test Program 2014–2019 (2020)
  5. FDA: Current thinking on pyrogen and endotoxins testing (2026)
  6. A Study on the Application of Recombinant Factor C Assay Using Biopharmaceuticals (2024)
  7. Low Endotoxin Recovery: Masking of Naturally Occurring Endotoxin (2019)
  8. FDA: Pyrogen and Endotoxins Testing, Questions and Answers, Edition 2 (March 2026)
  9. Residual Endotoxin Contaminations in Recombinant Proteins (2014)
  10. Evaluation of recombinant factor C for divergent LPS structural species (2017)
  11. NIBSC: WHO Third International Standard for endotoxin, code 10/178 (2018)